Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortization of Deferred Charges (2019 - 2021)

Agios Pharmaceuticals (AGIO) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $2.4 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Amortization of Deferred Charges rose 5.01% year-over-year to $2.4 million, compared with a TTM value of $9.4 million through Sep 2021, up 5.66%, and an annual FY2019 reading of $8.5 million, changed N/A over the prior year.
  • Amortization of Deferred Charges was $2.4 million for Q3 2021 at Agios Pharmaceuticals, up from $2.3 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.4 million in Q1 2021 and bottomed at $2.1 million in Q1 2019.
  • Average Amortization of Deferred Charges over 3 years is $2.2 million, with a median of $2.2 million recorded in 2020.
  • Peak annual rise in Amortization of Deferred Charges hit 9.71% in 2021, while the deepest fall reached 4.97% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $2.2 million in 2019, then grew by 2.97% to $2.3 million in 2020, then increased by 5.01% to $2.4 million in 2021.
  • Business Quant data shows Amortization of Deferred Charges for AGIO at $2.4 million in Q3 2021, $2.3 million in Q2 2021, and $2.4 million in Q1 2021.